1.54
-0.08 (-4.94%)
| Previous Close | 1.62 |
| Open | 1.63 |
| Volume | 7,154,567 |
| Avg. Volume (3M) | 1,895,771 |
| Market Cap | 115,552,760 |
| Price / Earnings (Forward) | 5.39 |
| Price / Book | 2.62 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -0.040 |
| Total Debt/Equity (MRQ) | 0.77% |
| Current Ratio (MRQ) | 13.90 |
| Operating Cash Flow (TTM) | -54.59 M |
| Levered Free Cash Flow (TTM) | -26.72 M |
| Return on Assets (TTM) | -40.10% |
| Return on Equity (TTM) | -38.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Eledon Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 68.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bvf Inc/Il | 30 Sep 2025 | 6,293,282 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 3,566,338 |
| Siren, L.L.C. | 30 Sep 2025 | 2,072,767 |
| Zimmer Partners, Lp | 30 Sep 2025 | 1,825,000 |
| Wellington Management Group Llp | 30 Sep 2025 | 1,283,939 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 1,280,233 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 1,264,919 |
| Catalio Capital Management, Lp | 30 Sep 2025 | 1,061,132 |
| Blue Owl Capital Holdings Lp | 30 Sep 2025 | 979,912 |
| Sanofi | 30 Sep 2025 | 814,980 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (HC Wainwright & Co., 484.42%) | Buy |
| Median | 8.50 (451.95%) | |
| Low | 8.00 (Guggenheim, 419.48%) | Buy |
| Average | 8.50 (451.95%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 8.00 (419.48%) | Buy | 1.54 |
| HC Wainwright & Co. | 02 Sep 2025 | 9.00 (484.42%) | Buy | 2.55 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |